Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Eupatorium capillifolium pollen is an allergenic extract derived from the pollen of the dog fennel plant. It is classified as a non-standardized biologic product and is used for both the diagnosis and treatment of allergies to this specific pollen. [2, 5, 6] For diagnosis, it is administered as part of a skin test to identify clinical sensitivity in a patient. For treatment, it is used in allergen immunotherapy (also known as hyposensitization), where gradually increasing doses of the extract are administered via subcutaneous injection. This process helps the immune system build tolerance to the allergen, reducing the severity of allergic reactions over time. [4] The product is marketed by several companies, including ALK-Abello, Inc., Jubilant Hollisterstier LLC, and Greer Laboratories, Inc.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Eupatorium capillifolium pollen.